Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Pain is a major clinical problem for many patients with pancreatic cancer and chronic
pancreatitis (CP).In pancreatic cancer, nearly 75% of patients suffer from pain at the time
of diagnosis, with over 90% of patients in advanced stages. In CP, pain occurs in 80-90% of
patients and strongly affects quality of life. For both conditions, the majority of pain is
addressed using the WHO analgesic ladder. However, more invasive pain therapies are often
necessary.
Currently, in several centers in the Netherlands, treatment with IV lidocaine is already used
in clinical practice in patients with pancreatic cancer and CP. Based on practical
experience, the majority of patients benefit from this therapy, however, its efficacy in
terms of duration of pain relief, decrease in pain scores, increase in patient satisfaction
and adverse events is unknown. Therefore, the aim of this study is to investigate the
efficacy of monitored single intravenous infusion in patients with pancreatic cancer and CP.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)